Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nabriva Therapeutics plc (NBRVF)
Dublin, IE
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +100.00% | +100.00% | +100.00% | -99.98% | -99.98% | -99.98% | -99.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+31.1% ★ Q2'23: -70.7% (vs Q2'22)
-
EPS growth Biotechnology: +29.7%+25.3% Q2'23: +14.8% (vs Q2'22)
-
FCF margin FCF growth · Biotechnology: +16.2%-121.8% Q2'23: +19.9% (vs Q2'22)
-
EBIT margin Biotechnology: +0.0%-154.0% Q2'23: -467.1% (vs Q2'22)
-
ROIC Biotechnology: -16.1%— Q2'23: +267.8% (vs Q2'22)
-
Share dilution Biotechnology: -3.4%+54.7% Q2'23: +27.7% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.10× Q2'23: -0.01× (vs Q2'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 5.50M (-100.0%)
|
—
est: 5.36M (-100.0%)
|
6.50M
est: 9.52M (-31.7%)
|
7.75M
est: 10.57M (-26.7%)
|
5.03M
est: 4.11M (+22.2%)
|
27.22M
est: 29.73M (-8.5%)
|
35.67M
est: 36.21M (-1.5%)
|
55.39M
est.
|
103.83M
est.
|
133.90M
est.
|
163.83M
163.83M – 163.83M
+22.3% YoY
|
| EBITDA |
-54.42M
est: -5.50M (-888.9%)
|
-72.53M
est: -5.36M (-1,251.9%)
|
-114.09M
est: -9.52M (-1,098.6%)
|
-78.72M
est: -10.57M (-644.8%)
|
-66.88M
est: -4.11M (-1,525.7%)
|
-47.42M
est: -29.73M (-59.5%)
|
-54.70M
est: -36.21M (-51.1%)
|
-55.39M
est.
|
-103.83M
est.
|
-133.90M
est.
|
-163.83M
-163.83M – -163.83M
-22.3% YoY
|
| EBIT |
-55.76M
est: -5.50M (-913.3%)
|
-72.96M
est: -5.36M (-1,260.0%)
|
-114.60M
est: -9.52M (-1,103.9%)
|
-79.49M
est: -10.57M (-652.0%)
|
-67.70M
est: -4.11M (-1,545.6%)
|
-48.06M
est: -29.73M (-61.6%)
|
-54.92M
est: -36.21M (-51.7%)
|
-55.39M
est.
|
-103.83M
est.
|
-133.90M
est.
|
-163.83M
-163.83M – -163.83M
-22.3% YoY
|
| Net Income |
-54.89M
est: -14.56B (+99.6%)
|
-74.36M
est: -1.74B (+95.7%)
|
-114.78M
est: -1.41B (+91.8%)
|
-82.76M
est: -769.16M (+89.2%)
|
-69.48M
est: -354.25M (+80.4%)
|
-49.45M
est: -73.08M (+32.3%)
|
-57.19M
est: -47.00M (-21.7%)
|
-22.61M
est.
|
-2.52M
est.
|
10.57M
est.
|
23.90M
23.90M – 23.90M
+126.1% YoY
|
| SGA |
13.44M
est: 31.53M (-57.4%)
|
29.47M
est: 30.74M (-4.1%)
|
41.74M
est: 54.54M (-23.5%)
|
62.49M
est: 60.57M (+3.2%)
|
55.29M
est: 23.57M (+134.5%)
|
51.65M
est: 170.38M (-69.7%)
|
45.26M
est: 207.48M (-78.2%)
|
317.38M
est.
|
594.97M
est.
|
767.29M
est.
|
938.75M
938.75M – 938.75M
+22.3% YoY
|
| EPS |
-638.90
est: -5,430.00 (+88.2%)
|
-623.15
est: -650.00 (+4.1%)
|
-564.91
est: -524.69 (-7.7%)
|
-278.75
est: -286.79 (+2.8%)
|
-135.23
est: -132.08 (-2.4%)
|
-28.52
est: -27.25 (-4.7%)
|
-21.32
est: -17.53 (-21.7%)
|
-8.43
est.
|
-0.94
est.
|
3.94
est.
|
8.91
8.91 – 8.91
+126.1% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alex Noah Investors, Inc. | 4.51M | 7.96% | — | 4.51M | — | — | CO | Illinois | 2021-11-19 | ↗ |
| 2 | Jonathan I. Cope | 4.51M | 7.96% | — | 4.51M | — | — | IN | Illinois | 2021-11-19 | ↗ |
| 3 | Joshua B. Scheinfeld | 4.51M | 7.96% | — | 4.51M | — | — | IN | Illinois | 2021-11-19 | ↗ |
| 4 | Lincoln Park Capital Fund, LLC | 4.51M | 7.96% | — | 4.51M | — | — | OO | Illinois | 2021-11-19 | ↗ |
| 5 | Lincoln Park Capital, LLC | 4.51M | 7.96% | — | 4.51M | — | — | OO | Illinois | 2021-11-19 | ↗ |
| 6 | Rockledge Capital Corporation | 4.51M | 7.96% | — | 4.51M | — | — | CO | Illinois | 2021-11-19 | ↗ |
| 7 | Juliet Tammenoms Bakker | 4.01M | 6.00% | — | 4.01M | — | 4.01M | IN | United States of America | 2018-08-07 | ↗ |
| 8 | Longitude Capital Partners II, LLC | 4.01M | 6.00% | — | 4.01M | — | 4.01M | OO | United States of America | 2018-08-07 | ↗ |
| 9 | Longitude Venture Partners II, L.P. | 4.01M | 6.00% | — | 4.01M | — | 4.01M | PN | United States of America | 2018-08-07 | ↗ |
| 10 | Patrick G. Enright | 4.01M | 6.00% | — | 4.01M | — | 4.01M | IN | United States of America | 2018-08-07 | ↗ |
| 11 | 0 | 3.15M | 15.91% | 3.15M | — | 3.15M | — | OO | Delaware | 2015-09-25 | ↗ |
| 12 | OrbiMed Advisors LLC | 307.2K | 14.52% | — | 307.2K | — | 10.00 | IA | Delaware | 2015-10-02 | ↗ |
| 13 | OrbiMed Capital GP V LLC | 307.2K | 14.52% | — | 307.2K | — | 10.00 | OO | Delaware | 2015-10-02 | ↗ |
| 14 | Samuel D. Isaly | 307.2K | 14.52% | — | 307.2K | — | 10.00 | IN | United States | 2015-10-02 | ↗ |
| 15 | HBM Healthcare Investments (Cayman) Ltd. | 276.0K | 13.04% | 276.0K | — | 276.0K | — | CO | Cayman Islands, British West Indies | 2015-10-05 | ↗ |
| 16 | Corey Goodman | 117.8K | 5.60% | — | 117.8K | — | 117.8K | IN | Cayman Islands | 2016-04-29 | ↗ |
| 17 | Robert Adelman | 117.8K | 5.60% | — | 117.8K | — | 117.8K | IN | Cayman Islands | 2016-04-29 | ↗ |
| 18 | venBio Global Strategic Fund II, L.P. | 117.8K | 5.60% | — | 117.8K | — | 117.8K | PN | Cayman Islands | 2016-04-29 | ↗ |
| 19 | venBio Global Strategic GP II, L.P. | 117.8K | 5.60% | — | 117.8K | — | 117.8K | PN | Cayman Islands | 2016-04-29 | ↗ |
| 20 | HBM BioCapital Invest Ltd. | 39.2K | 1.85% | 39.2K | — | 39.2K | — | CO | Cayman Islands, British West Indies | 2015-10-05 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Colin Broom | Director | 40.0K | — |
| David Maggio | Chief Financial Officer | — | male |
| H. Michael Hogan | Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NBRVF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
